In comb­ing through thou­sands of C-suite pay pack­ages worth bil­lions of dol­lars, it’s rare for a line item to stick out.

Every once in a...

Sci­wind Bio­sciences has al­ready li­censed its GLP-1 obe­si­ty drug ec­nog­lu­tide twice over — to Pfiz­er and Ver­di­va Bio — but it is not done yet...

Plus news about Cari­bou, Adi­al, and the Beneluxa Ini­tia­tive.

💵 En­liv­en Ther­a­peu­tics’ da­ta and raise: The Burlingame, CA-based biotech priced a $400 mil­lionof­fer­ing ELVN...

GSK’s $10.6 bil­lion buy­out of Nu­va­lent, an­nounced Tues­day, was the largest in the com­pa­ny’s his­to­ry. But did new CEO Luke Miels get a dis­count...

WuXi AppTec has lodged a claim against the De­part­ment of De­fense fol­low­ing its ad­di­tion to a list of com­pa­nies as­so­ci­at­ed with the Chi­nese mil­i­tary.

Un­der...

For­bion’s port­fo­lio com­pa­nies have been no stranger to M&A deals in re­cent years. But the Dutch in­vest­ment firm now wants more of its...